Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Immune Design (Seattle, WA) a development-stage therapeutic vaccine company focused on oncology and infectious disease, closed a $32M Series B financing. Participants include ProQuest Investments, Column Group, Versant Ventures and Alta Partners.

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $30M Series F financing. Participants have included Canaan Partners, Radius Ventures, Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capitaland […]

Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage small molecule company focused on isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, closed a $40M Series C financing. Participants include Quogue Capital, Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners.

Mirina (Seattle, WA) a development-stage biotechnology company focused on miRNA therapeutics for oncology and metabolic disorders, closed a $3.9M Series A financing, bringing the total round to $7.5M. Participants include Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

Coronado Biosciences (Seattle, WA) a clinical-stage biopharmaceutical oncology company focused on AML, NSCLC, leukemia, lymphoma, and prostate cancer. Participants were not identified.

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $21.5M Series E financing. Participants have included Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capitaland Oakwood Medical Investors. Note: […]

Integrated Diagnostics (Seattle, WA) a development-stage diagnostics company focused on rapid biomarker validation and parallel organ-centric assays, closed a $30M Series A financing. Participants include Interwest Partners, The Wellcome Trust and Dievini Hopp Biotech Holding. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $21.5 Series E financing. Participants have included Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capital and Oakwood Medical Investors. […]

Calypso Medical Technologies (Seattle, WA) a commercial-stage medical device company focused on implantable sensor electromagnetic transponders, to accurately and continuously pinpoint the location of tumors in real-time during radiation therapy delivery, closed a $50M Series E financing. Participants include Skyline Ventures, Frazier Healthcare Ventures, Bay City Capital and InterWest Partners.

NanoString Technologies (Seattle, WA) a commercial-stage developer of instrumentation and assays for multiplexed detection and quantification of gene expression, closed a $30M Series C financing. Participants include Clarus Ventures, OVP Venture Partners and Draper Fisher Jurvetson.

Pathway Medical Technologies (Kirkland, WA) development-stage medical company focused on peripheral-arterial disease, closed a $42.5M Series D financing. Participants include HLM Venture Partners, Latterell Venture Partners, Oxford Bioscience Partners, Forbion Capital Partners, Giza Venture Capital and WRF Capital.

MediQuest Therapeutics (Bothell, WA) a late-stage specialty pharmaceutical company focused on inflammatory and infectious diseases such as Raynaud’s, nail psoriasis and actinic keratosis, closed a $23M Series B financing. Participants were not named however, Series A participants included Novo Ventures, Janus, Integra Ventures and Masa Life Science Fund.

Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage biopharmaceutical company focused on the PI3 kinase pathway in oncology and inflammatory disease, closed a $30M Series B financing. Participants include Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...